India’s drug regulator has inspected nearly 90% of the country’s cough syrup makers and found compliance lapses, its chief said on Monday, amid heightened scrutiny after India-made syrups were linked to the deaths of children in the country and abroad. The inspections follow the discovery of a brand of cough syrup contaminated with diethylene glycol that was linked to the deaths of 24 children in October last year. The product, named Coldrif, was made by Sresan Pharmaceutical, based in Tamil Nadu. “We took serious actions on serious non-compliances, and our belief is that the rot of cough syrup manufacturing will be removed,” Drugs Controller General of India Rajeev Raghuvanshi said at the IPA 11th Global Pharmaceutical Quality Summit in Mumbai. The regulator is looking to fix issues around cough syrup products, he said, without providing a timeline. Read More: WHO identifies India-made contaminated cough syrup in Western Pacific The agency is under pressure to tighten oversight of the...
President Donald Trump renewed his condemnation of the United States Supreme Court on Monday after it ruled against his sweeping tariff program last week, vowing to turn to other tariff powers and licenses but giving no details. "The court has also approved all other tariffs, of which there are many, and they can all be used in a much more powerful and obnoxious way, with legal certainty, than the tariffs as initially used," he wrote in a social media post. https://ift.tt/FWpkQBR Trump said on Saturday he would raise a temporary tariff from 10% to 15% on US imports from all countries, the maximum level allowed under the law, a day after the court ruled that Trump had exceeded his presidential authority when he imposed an array of higher tariff rates under an economic emergency law. In his post today, Trump also pointed to the potential use of licenses to pressure countries, writing that "incomprehensibly, according to the ruling, [I] can’t charge them a licence fee — but...